Jinhe Biotechnology released its 2026 interim report. Total operating revenue was 1.448 billion yuan, and net profit attributable to the parent company was 131 million yuan, a decrease of 7.0245 million yuan from the same period last year, down 5.09% year-on-year. Net cash inflow from operating activities was 254 million yuan, the asset-liability ratio was 56.10%, gross margin was 37.78%, and diluted earnings per share was 0.17 yuan, down 4.81% year-on-year. The number of shareholders was 44,500, and the top ten shareholders held 37.94% of total share capital.
Jinhe Biotechnology Co LtdNet profit fell 5.09% year-on-year, missing prior performance.
